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Background
There is no published evidence on how JDM is currently
treated in UK and Irish paediatric rheumatology centres.
Aim
To confirm whether current treatment agrees with phy-
sician’s perception of their treatment practices.
Methods
We compared the results of a survey of current practice
throughout the UK and Ireland with data prospectively
collected since January 2000 from the UK JDM cohort
study. Patients were classified as having mild, moderate
or severe disease at presentation according to their Phy-
sicians Global Assessment (PGA) at diagnosis.
Results
Fifteen of 16 Paediatric Rheumatology centres
responded to the survey. For initial treatment of patients
with mild disease 13/15 centres report using a combina-
tion of steroids and methotrexate and 8/15 would also
use IV methylprednisolone. For moderately severe dis-
ease all centres use steroids and methotrexate and 11/15
also use IV methylprednisolone. With severe weakness,
ulceration or systemic disease all centres use IV methyl-
prednisolone as initial treatment, 13/15 use methotrex-
ate and 9/15 use cyclophosphamide.
Prospective data were analysed from 98 patients in
the UK JDM cohort study. A combination of steroids
and methotrexate was used in the first year of treat-
ment in 78% of patients with mild disease (PGA 0-
3.3cm), 89% of patients with moderately severe disease
(PGA 3.4-6.7cm) and 100% of patients with severe dis-
ease (PGA 6.8-10cm). Cyclophosphamide was used
within the first year of diagnosis in 16% of patients
with mild disease at presentation, 19% of patients with
moderately severe disease and 38% of those with severe
disease (p=0.05). There was no significant association
between severity of disease at diagnosis and the use of
intravenous steroids.
Conclusions
Our study confirms that steroids and methotrexate
form the basis of first line therapy in JDM throughout
the UK and Ireland. Cyclophosphamide is commonly
used for patients with severe disease, systemic involve-
ment or cutaneous ulceration, suggesting that a con-
sensus could be reached on treatment protocols within
the UK.
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